<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091324</url>
  </required_header>
  <id_info>
    <org_study_id>HR-97-108</org_study_id>
    <nct_id>NCT01091324</nct_id>
  </id_info>
  <brief_title>Dextromethorphan and Silymarin in Chronic Kidney Disease (CKD) Patients</brief_title>
  <acronym>CKD</acronym>
  <official_title>The Reno-protective and Cardiovascular Effect of Dextromethorphan and Silymarin in Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators test the renal and cardiovascular protective effects dextromethorphan and
      silymarin on patients with the proteinuric chronic kidney diseases, who enrolled in our
      clinical trial, had progressing kidney diseases and merit aggressive anti-inflammatory
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of eGFR</measure>
    <time_frame>4 months</time_frame>
    <description>Use MDRD-simplified equation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Urine TP/Cr</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of serum hsCRP</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of urine TGF-beta/Cr level</measure>
    <time_frame>4 months</time_frame>
    <description>fibrotic marker of kidney</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>4 months</time_frame>
    <description>by Flow-mediated dilatation mesured by Crdiovascular ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leukocyte ROCK activity</measure>
    <time_frame>4 months</time_frame>
    <description>Measure leukocyte Ro kinase activity by western blotting This is an indicator of cardiovascular function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood MDA level</measure>
    <time_frame>4 months</time_frame>
    <description>Indicator of oxidative stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood TGF-beta</measure>
    <time_frame>4 months</time_frame>
    <description>By Elisa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine MCP-1/Cr level</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Proteinuria</condition>
  <arm_group>
    <arm_group_label>Dextromethorphan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Silymarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan</intervention_name>
    <description>60 mg, bid</description>
    <arm_group_label>Dextromethorphan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin</intervention_name>
    <description>150 mg , tid</description>
    <arm_group_label>Silymarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugar pill</intervention_name>
    <description>placebo</description>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with Stage 3 or 4 chronic kidney disease as measured by a Modification in
             Diet in Renal Disease Study (MDRD) estimate of between 15 ml/min and 59 ml/min and and
             0.5 g/day&lt;proteinuria&lt;3g/day.

          2. Age between 18 and 75 years old.

          3. Patients without hospitalization for cardiac or infection related morbidity over the
             previous 2 months(due to the potential confounding effects on baseline study
             variables).

          4. Patients who are able to provide consent to participate in the study.-

        Exclusion Criteria:

          1. patients will significant mental illness, pregnant women, and other vulnerable
             populations.

          2. Patients with active hepatic disease and/or ALT &gt; 2.5 times upper limit of normal.

          3. Patients with history of congestive heart failure and NYHA Class III-IV symptoms at
             any time.

          4. Patients for whom living donor renal transplantation is already scheduled or in the
             process of being evaluated, as these patients will be unlikely to complete study
             protocols before transplantation.

          5. Patients with severe co-morbid conditions (eg, symptomatic hepatic cirrhosis,
             metastatic cancer, HIV infection with AIDS).

          6. Patient with active inflammatory process (eg., SLE, rheumatoid arthritis, gout) for
             which they are currently receiving immune modulating medications.

          7. Patients who are on corticosteroid therapy.

          8. Patients who do not consent to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junne-Ming Sung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Taian</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <last_update_submitted>March 22, 2010</last_update_submitted>
  <last_update_submitted_qc>March 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Junne-Ming Sung</name_title>
    <organization>National Cheng Kung University Hospital (NCKUH)</organization>
  </responsible_party>
  <keyword>CKD, proteinuria, dextromethorphan, silymarin</keyword>
  <keyword>patients with 15 ml&lt;eGFR&lt; 60ml and 0.5 g/day&lt;proteinuria&lt;3g/day</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Silymarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

